Bioheart (02185.HK) announces clinical result for Iberis-HTN at CIT 2023 ...Middle East

SHANGHAI, June 29, 2023 /PRNewswire/ -- Bioheart (02185.HK), together with its holding subsidiary Angiocare announces the clinical result for Iberis-HTN at China Interventional Therapeutics 2023. Iberis-HTN is a prospective, multicenter, blinded, randomized controlled trial to evaluate...

Hence then, the article about bioheart 02185 hk announces clinical result for iberis htn at cit 2023 was published today ( Friday 30/06/2023 - 06:32 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Bioheart (02185.HK) announces clinical result for Iberis-HTN at CIT 2023 )

Also on site :

• Gold Star Distribution Inc., Issues Recall of Certain FDA-Regulated Products in Three States Including Drugs, Devices, Cosmetics, Human Foods, and Pet Foods
• ’Beverly Hills, 90210’s Jason Priestley Shares Bold Callout After ‘Worst’ Travel Experience
• Central African Republic election: Who’s running and what’s at stake?